These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2525981)

  • 1. Profile of etodolac: pharmacokinetic evaluation in special populations.
    Brater DC; Lasseter KC
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():25-35. PubMed ID: 2525981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic study of etodolac after rectal administration; "in vitro" release kinetics.
    Cadorniga R; Herrero R; Barcia E; Molina IT; Guitierrez JA; Fabregas JL; Martinez-Tobed A
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():389-96. PubMed ID: 1840326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the antiarthritic efficacy and safety of etodolac.
    Zvaifler N
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():43-53. PubMed ID: 2525982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etodolac kinetics in the elderly.
    Scatina J; Hicks D; Kraml M; Weidler D; Garg D; Sanda M
    Clin Pharmacol Ther; 1986 May; 39(5):550-3. PubMed ID: 2938866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic difference between S-(+)- and R-(-)-etodolac in rats.
    Shi JM; Lai SG; Xu CJ; Duan GL; Li D
    Acta Pharmacol Sin; 2004 Aug; 25(8):996-9. PubMed ID: 15301730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of etodolac in subjects with renal impairment.
    Brater DC
    Eur J Rheumatol Inflamm; 1990; 10(1):44-55. PubMed ID: 2146131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etodolac clinical pharmacokinetics.
    Brocks DR; Jamali F
    Clin Pharmacokinet; 1994 Apr; 26(4):259-74. PubMed ID: 8013160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic profile of etodolac in special populations.
    Benet LZ
    Eur J Rheumatol Inflamm; 1994; 14(1):15-8. PubMed ID: 7744123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereoselective disposition of etodolac enantiomers in synovial fluid.
    Brocks DR; Jamali F; Russell AS
    J Clin Pharmacol; 1991 Aug; 31(8):741-6. PubMed ID: 1831817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effectiveness and safety of etodolac in prolonged treatment of active osteoarthritis.
    Puccetti L; Ciompi ML
    Int J Clin Pharmacol Res; 1991; 11(3):143-58. PubMed ID: 1839736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee.
    Astorga Paulsen G; Baigun S; Galvao de Figueiredo J; Gomes de Freitas G
    Curr Med Res Opin; 1991; 12(6):401-12. PubMed ID: 1828415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single and repeated dose pharmacokinetics of dexketoprofen trometamol in patients with impaired liver function.
    Valles J; Artigas R; Bertolotti M; Crea A; Muller F; Paredes I; Capriati A
    Methods Find Exp Clin Pharmacol; 2006 Jun; 28 Suppl A():29-36. PubMed ID: 16801990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
    Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
    Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of severity of chronic inflammatory joint disease on the pharmacokinetics of indomethacin and etodolac.
    Pawlotsky Y; Le Dantec P; Jacquelinet C; Lapicque F; Goasguen J; Perdriger A; Veillard E; Guggenbuhl P; Netter P
    Rev Rhum Engl Ed; 1996 Mar; 63(3):179-87. PubMed ID: 8731235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chiral bioequivalence: effect of absorption rate on racemic etodolac.
    Boni JR; Korth-Bradley JM; Richards LS; Chiang ST; Hicks DR; Benet LZ
    Clin Pharmacokinet; 2000 Dec; 39(6):459-69. PubMed ID: 11192477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam.
    Crevoisier C; Zaugg PY; Heizmann P; Meyer J
    Int J Clin Pharmacol Res; 1989; 9(5):327-34. PubMed ID: 2625372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
    Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
    Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenac.
    Manvelian G; Daniels S; Gibofsky A
    Postgrad Med; 2012 Jan; 124(1):117-23. PubMed ID: 22314121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies.
    Lanza FL; Arnold JD
    Clin Rheumatol; 1989 Mar; 8 Suppl 1():5-15. PubMed ID: 2525983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.